FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL								
OMB Number: 3235-0287								
Estimated average burden								
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*     Olivo Martin Sebastian					2. Issuer Name and Ticker or Trading Symbol Protara Therapeutics, Inc. [ TARA ]							(Che	eck all application	able)		Ssuer Owner (specify
(Last) (First) (Middle) C/O PROTARA THERAPEUTICS, INC.					3. Date of Earliest Transaction (Month/Day/Year) 04/19/2021							X Officer (give title Other (specify below)  Chief Medical Officer				
345 PARK AVENUE SOUTH, 3RD FLOOR					4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable				
(Street) NEW YO	ORK N	Y	10010									Line	Form fil	,	Reporting Pers	
(City)	(S	tate)	(Zip)													
		Та	ble I - Non	-Deriva	tive S	ecuritie	s Acc	quired, I	Disp	osed c	f, or Be	neficially	/ Owned			
1. Title of Security (Instr. 3)  2. Transa Date (Month/D				Execution Date,			Code (Instr.				5. Amount Securities Beneficia Owned For Reported	s F lly ( ollowing (	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
								Code	v	Amount	ount (A) or (D)		Transaction(s) (Instr. 3 and 4)			(insti. 4)
			Table II - I (			curities IIs, warr							Owned			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	Date Exe (Month/Day/Year) if a	3A. Deemed Execution Da if any (Month/Day/Y	Cod	nsaction e (Instr.	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable ar Expiration Date (Month/Day/Year)			7. Title and Amo of Securities Underlying Derivative Secu (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction	Ownersl Form: Direct (Dor Indire (I) (Instr.	Beneficial Ownership ct (Instr. 4)
_				Cod	e V	(A)		Date Exercisabl		xpiration ate	Title	Amount or Number of Shares		(Instr. 4)		
Stock Option (Right to Buy)	\$15.3	04/19/2021		A		120,000		(1)	0.	4/18/2031	Common Stock	120,000	\$0.00	120,000	) D	

## **Explanation of Responses:**

1. One-fourth of the shares shall vest on April 19, 2022 and the remainder of the shares will vest in a series of thirty-six successive equal monthly installments measured from April 19, 2022, subject to the Reporting Person's Continuous Service (as defined in the Inducement Plan) with the Issuer through each such vesting date.

## Remarks:

/s/ Karen Deschaine, Attorneyin-fact

\*\* Signature of Reporting Person

04/20/2021

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.